Genmab's Rina-S improves progression-free survival in Phase 3 ovarian cancer trial
GMAB•Genmab said Rina-S significantly improved progression-free and overall survival versus chemotherapy in the Phase 3 RAINFOL-02 trial. In the 584-patient intent-to-treat population, it reduced the risk of disease progression or death by 71% and the risk of death by 57%.
1. Trial results
Genmab said its investigational drug Rina-S significantly improved progression-free and overall survival versus chemotherapy in the Phase 3 RAINFOL-02 trial for platinum-resistant ovarian cancer. In the intent-to-treat population of 584 patients, regardless of folate receptor alpha expression or prior mirvetuximab treatment, Rina-S reduced the risk of disease progression or death by 71% and the risk of death by 57%.
2. Safety and next steps
The safety profile was consistent with previous findings, with no new safety signals or unexpected concerns. Genmab plans to discuss potential next steps with regulatory authorities worldwide.
